Nanocarry is developing a new class of therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases. Using a proprietary “Plug and Play” approach, Nanocarry’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond. Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.

Biotechnology

Nanotechnology

Therapeutics

Nanocarry

Nanocarry's headquarters in Ness Ziona, Israel

People (4)

Jobs (0)

Other offices